

Frank Speleman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5568027/publications.pdf>

Version: 2024-02-01

437
papers

49,276
citations

3933

88
h-index

1825

210
g-index

461
all docs

461
docs citations

461
times ranked

61107
citing authors

#	ARTICLE	IF	CITATIONS
1	The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. <i>European Journal of Cancer</i> , 2022, 160, 12-23.	2.8	16
2	Cellular senescence in neuroblastoma. <i>British Journal of Cancer</i> , 2022, 126, 1529-1538.	6.4	5
3	RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. <i>Science Advances</i> , 2022, 8, .	10.3	15
4	PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. <i>Leukemia</i> , 2021, 35, 679-690.	7.2	11
5	Recurrent chromosomal imbalances provide selective advantage to human embryonic stem cells under enhanced replicative stress conditions. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 272-281.	2.8	3
6	Kalirin-RAC controls nucleokinetic migration in ADRN-type neuroblastoma. <i>Life Science Alliance</i> , 2021, 4, e201900332.	2.8	4
7	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. <i>Cancers</i> , 2021, 13, 1807.	3.7	4
8	MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells. <i>Scientific Reports</i> , 2021, 11, 14454.	3.3	6
9	MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation. <i>Cancers</i> , 2021, 13, 4783.	3.7	12
10	From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1286.	2.5	2
11	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. <i>European Journal of Pediatrics</i> , 2020, 179, 191-202.	2.7	55
12	Large-scale circular RNA deregulation in T-ALL: unlocking unique ectopic expression of molecular subtypes. <i>Blood Advances</i> , 2020, 4, 5902-5914.	5.2	39
13	PHF6 Expression Levels Impact Human Hematopoietic Stem Cell Differentiation. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 599472.	3.7	8
14	Distinct Notch1 and <i>BCL11B</i> requirements mediate human $\hat{1}^{\hat{1}}/\hat{1}^{\pm}\hat{1}^2$ T cell development. <i>EMBO Reports</i> , 2020, 21, e49006.	4.5	31
15	A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models. <i>Leukemia</i> , 2020, 34, 3398-3403.	7.2	12
16	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , 2020, 136, 52-68.	2.8	42
17	The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness. <i>Scientific Reports</i> , 2020, 10, 218.	3.3	20
18	SMARTer single cell total RNA sequencing. <i>Nucleic Acids Research</i> , 2019, 47, e93-e93.	14.5	38

#	ARTICLE	IF	CITATIONS
19	Purification of high-quality RNA from a small number of fluorescence activated cell sorted zebrafish cells for RNA sequencing purposes. BMC Genomics, 2019, 20, 228.	2.8	10
20	Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes. Scientific Reports, 2019, 9, 5685.	3.3	14
21	DREAM target reactivation by core transcriptional regulators supports neuroblastoma growth. Molecular and Cellular Oncology, 2019, 6, 1-3.	0.7	1
22	Long noncoding RNA expression profiling in cancer: Challenges and opportunities. Genes Chromosomes and Cancer, 2019, 58, 191-199.	2.8	117
23	Pinpointing a potential role for <i>CLEC12B</i> in cancer predisposition through familial exome sequencing. Pediatric Blood and Cancer, 2019, 66, e27513.	1.5	3
24	ALK positively regulates MYCN activity through repression of HBP1 expression. Oncogene, 2019, 38, 2690-2705.	5.9	17
25	Abstract 3696:PHF6loss drives IL7R oncogene addiction in TLX1 driven T-ALL. , 2019, , .		0
26	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73
27	Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. Cancer Research, 2018, 78, 3122-3134.	0.9	48
28	Epigenetic regulation of neuroblastoma development. Cell and Tissue Research, 2018, 372, 309-324.	2.9	36
29	Promoter-associated proteins of EPAS1 identified by enChIP-MS – A putative role of HDX as a negative regulator. Biochemical and Biophysical Research Communications, 2018, 499, 291-298.	2.1	10
30	TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Nature Communications, 2018, 9, 4866.	12.8	91
31	Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. Science Signaling, 2018, 11, .	3.6	33
32	A mechanistic classification of clinical phenotypes in neuroblastoma. Science, 2018, 362, 1165-1170.	12.6	213
33	In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors. Scientific Reports, 2018, 8, 17468.	3.3	11
34	Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice. Scientific Reports, 2018, 8, 7642.	3.3	10
35	A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing. Haematologica, 2018, 103, e585-e589.	3.5	20
36	Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia. Leukemia, 2018, 32, 1860-1865.	7.2	23

#	ARTICLE	IF	CITATIONS
37	Vehicle development, pharmacokinetics and toxicity of the anti-invasive agent 4-fluoro-3- β -D-glucopyranoside, 4- β -D-glucopyranoside-trimethoxychalcone in rodents. PLoS ONE, 2018, 13, e0192548.	2.5	8
38	A high-throughput 3' UTR reporter screening identifies microRNA interactomes of cancer genes. PLoS ONE, 2018, 13, e0194017.	2.5	15
39	LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis. Clinical Cancer Research, 2018, 24, 5772-5783.	7.0	48
40	Meta-mining of copy number profiles of high-risk neuroblastoma tumors. Scientific Data, 2018, 5, 180240.	5.3	27
41	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight, 2018, 3, .	5.0	28
42	The mutational landscape of MYCN, Lin28b and ALK F1174L driven murine neuroblastoma mimics human disease. Oncotarget, 2018, 9, 8334-8349.	1.8	6
43	T-ALL and thymocytes: a message of noncoding RNAs. Journal of Hematology and Oncology, 2017, 10, 66.	17.0	24
44	Long non-coding RNAs in leukemia: biology and clinical impact. Current Opinion in Hematology, 2017, 24, 353-358.	2.5	15
45	Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients. Clinical Cancer Research, 2017, 23, 6305-6314.	7.0	113
46	Comprehensive miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing. Scientific Reports, 2017, 7, 7901.	3.3	49
47	Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma. Oncotarget, 2017, 8, 57047-57057.	1.8	19
48	Abstract 5506: SOX11 acts as part of the MYCN-WEE1 regulatory protein complex implicated in neuroblastoma. , 2017, , .		1
49	Targeting tachykinin receptors in neuroblastoma. Oncotarget, 2017, 8, 430-443.	1.8	19
50	Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome. Oncotarget, 2017, 8, 106820-106832.	1.8	2
51	Abstract 1527: BRD3 as a specific vulnerable therapeutic target in neuroblastoma. , 2017, , .		0
52	Abstract 4886: The BRIP1 DNA helicase is a 17q dosage sensitive cooperative driver in neuroblastoma. , 2017, , .		0
53	Abstract 5815: The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex. , 2017, , .		0
54	Abstract LB-051: High LDHA expression predicts decreased survival in neuroblastoma. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
55	Neuroblastoma: A Tough Nut to Crack. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e548-e557.	3.8	37
56	GATA3 induces human T-cell commitment by restraining Notch activity and repressing NK-cell fate. Nature Communications, 2016, 7, 11171.	12.8	57
57	Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples. Scientific Reports, 2016, 6, 37876.	3.3	17
58	Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Molecular Oncology, 2016, 10, 866-878.	4.6	23
59	Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia. Leukemia, 2016, 30, 1927-1930.	7.2	32
60	Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait. Epigenetics, 2016, 11, 761-771.	2.7	24
61	RT-qPCR gene expression analysis in zebrafish. Methods in Cell Biology, 2016, 135, 329-342.	1.1	8
62	LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. Blood, 2016, 127, 1163-1172.	1.4	48
63	DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing. Scientific Data, 2016, 3, 160004.	5.3	11
64	LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19. Haematologica, 2016, 101, e240-e244.	3.5	18
65	Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. Clinical Cancer Research, 2016, 22, 2470-2481.	7.0	147
66	RPPA-Based Protein Profiling Reveals Enhanced PI3K/AKT/mTOR Signaling in ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia Patients with Low CD200 Expression. Blood, 2016, 128, 890-890.	1.4	1
67	MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. Oncotarget, 2016, 7, 66344-66359.	1.8	30
68	Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Oncotarget, 2016, 7, 73769-73780.	1.8	30
69	Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. Oncotarget, 2016, 7, 1960-1972.	1.8	26
70	Abstract A28: Expanding the TLX1 regulome in T-cell acute lymphoblastic leukemia towards long noncoding RNAs. , 2016, , .		0
71	Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study. Blood, 2016, 128, 1743-1743.	1.4	0
72	Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma. Cancer Cell International, 2015, 15, 76.	4.1	38

#	ARTICLE	IF	CITATIONS
73	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 13-21.	1.4	168
74	MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma. <i>Molecular and Cellular Pediatrics</i> , 2015, 2, A13.	1.8	0
75	ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. <i>Nature Communications</i> , 2015, 6, 5794.	12.8	75
76	<i>miR-135a</i> Inhibits Cancer Stem Cell-Driven Medulloblastoma Development by Directly Repressing <i>Arhgef6</i> Expression. <i>Stem Cells</i> , 2015, 33, 1377-1389.	3.2	35
77	MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma. <i>Cancer Letters</i> , 2015, 366, 123-132.	7.2	51
78	Novel biological insights in T-cell acute lymphoblastic leukemia. <i>Experimental Hematology</i> , 2015, 43, 625-639.	0.4	97
79	Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2015, 29, 2317-2327.	7.2	23
80	Molecular basis and clinical significance of genetic aberrations in B-cell precursor acute lymphoblastic leukemia. <i>Experimental Hematology</i> , 2015, 43, 640-653.	0.4	20
81	Mutational dynamics between primary and relapse neuroblastomas. <i>Nature Genetics</i> , 2015, 47, 872-877.	21.4	253
82	A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. <i>Oncogene</i> , 2015, 34, 3357-3368.	5.9	112
83	Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma. <i>Scientific Reports</i> , 2015, 5, 9027.	3.3	29
84	Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 3327-3339.	7.0	76
85	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. <i>Science Translational Medicine</i> , 2015, 7, 312ra176.	12.4	120
86	Refinement of the critical 2p25.3 deletion region: the role of MYT1L in intellectual disability and obesity. <i>Genetics in Medicine</i> , 2015, 17, 460-466.	2.4	45
87	Epigenetics in T-cell acute lymphoblastic leukemia. <i>Immunological Reviews</i> , 2015, 263, 50-67.	6.0	61
88	<i>miR-542b-3p</i> exerts tumor suppressive functions in neuroblastoma by downregulating <i>Survivin</i> . <i>International Journal of Cancer</i> , 2015, 136, 1308-1320.	5.1	78
89	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. <i>Clinical Cancer Research</i> , 2015, 21, 1904-1915.	7.0	80
90	MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2015, 29, 798-806.	7.2	91

#	ARTICLE	IF	CITATIONS
91	MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation. <i>Oncotarget</i> , 2015, 6, 5204-5216.	1.8	38
92	CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol. <i>Haematologica</i> , 2015, 100, 1311-1319.	3.5	8
93	Abstract 4731: Targeting super-enhancer induced gene expression with the novel BRD4 inhibitor OTX015 in preclinical models of MYCN-amplified neuroblastoma. , 2015, , .		0
94	Abstract B05: Transcriptional antagonism between the cooperative oncogenes TLX1 and NOTCH1 in T-cell acute lymphoblastic leukemia.. , 2015, , .		0
95	Expressed Repeat Elements Improve RT-qPCR Normalization across a Wide Range of Zebrafish Gene Expression Studies. <i>PLoS ONE</i> , 2014, 9, e109091.	2.5	38
96	ViVar: A Comprehensive Platform for the Analysis and Visualization of Structural Genomic Variation. <i>PLoS ONE</i> , 2014, 9, e113800.	2.5	45
97	CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. <i>PLoS ONE</i> , 2014, 9, e114696.	2.5	15
98	Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma. <i>Cancer Research</i> , 2014, 74, 765-774.	0.9	47
99	Emergence of New <i>ALK</i> Mutations at Relapse of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2727-2734.	1.6	176
100	Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia. <i>Science Signaling</i> , 2014, 7, ra111.	3.6	36
101	MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 1326-1333.	3.5	55
102	The H3K27me3 demethylase UTX in normal development and disease. <i>Epigenetics</i> , 2014, 9, 658-668.	2.7	109
103	Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. <i>Nature Communications</i> , 2014, 5, 4767.	12.8	421
104	A nanobody modulates the p53 transcriptional program without perturbing its functional architecture. <i>Nucleic Acids Research</i> , 2014, 42, 12928-12938.	14.5	32
105	The epigenetic landscape of T-cell acute lymphoblastic leukemia. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 547-557.	2.8	20
106	Lack of association betweenMDM2promoter SNP309 and clinical outcome in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1867-1870.	1.5	5
107	The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 1808-1816.	3.5	50
108	RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. <i>Nature</i> , 2014, 513, 65-70.	27.8	506

#	ARTICLE	IF	CITATIONS
109	Mate pair sequencing for the detection of chromosomal aberrations in patients with intellectual disability and congenital malformations. <i>European Journal of Human Genetics</i> , 2014, 22, 652-659.	2.8	32
110	Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. <i>Cancer Letters</i> , 2014, 344, 157-165.	7.2	39
111	ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 3738-3747.	1.4	198
112	Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. <i>Oncotarget</i> , 2014, 5, 2688-2702.	1.8	89
113	Emergence of new <i>ALK</i> mutations at relapse of neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11006-11006.	1.6	0
114	Abstract 3967: BET protein inhibitor OTX015 has selective anti-tumoral activity in preclinical models of MYCN- amplified neuroblastoma. , 2014, , .		0
115	Prognostic Relevance of CD200/Btla Deletions in Pediatric Precursor-B Cell Acute Lymphoblastic Leukemia Treated According to the EORTC-CLG 58951 Protocol. <i>Blood</i> , 2014, 124, 2394-2394.	1.4	0
116	The NOTCH1 Driven Long Non-Coding RNA Repertoire in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 900-900.	1.4	0
117	Transcriptional Antagonism Between the Cooperative Oncogenes TLX1 and NOTCH1 in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3588-3588.	1.4	0
118	MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. <i>Oncogene</i> , 2013, 32, 1059-1065.	5.9	84
119	Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. <i>Oncogene</i> , 2013, 32, 2927-2936.	5.9	84
120	Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2013, 27, 1603-1606.	7.2	22
121	MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. <i>International Journal of Cancer</i> , 2013, 133, 1064-1073.	5.1	91
122	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. <i>PLoS Genetics</i> , 2013, 9, e1003997.	3.5	110
123	Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. <i>Blood</i> , 2013, 121, 2415-2423.	1.4	61
124	Dynamic Activity of miR-125b and miR-93 during Murine Neural Stem Cell Differentiation In Vitro and in the Subventricular Zone Neurogenic Niche. <i>PLoS ONE</i> , 2013, 8, e67411.	2.5	30
125	Effective Alu Repeat Based RT-Qpcr Normalization in Cancer Cell Perturbation Experiments. <i>PLoS ONE</i> , 2013, 8, e71776.	2.5	13
126	A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma. <i>PLoS ONE</i> , 2013, 8, e79843.	2.5	34

#	ARTICLE	IF	CITATIONS
127	Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes. PLoS ONE, 2013, 8, e52321.	2.5	37
128	CLL Cells Respond to B-Cell Receptor Stimulation with a MicroRNA/mRNA Signature Associated with MYC Activation and Cell Cycle Progression. PLoS ONE, 2013, 8, e60275.	2.5	31
129	BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget, 2013, 4, 2080-2095.	1.8	122
130	Abstract 4596: LIN28B drives neuroblastoma oncogenesis through let7-MYCN signaling.. , 2013, , .		0
131	Expanding The TLX1-Regulome In T Cell Acute Lymphoblastic Leukemia Towards Long Non-Coding RNAs. Blood, 2013, 122, 813-813.	1.4	0
132	Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro-Oncology, 2012, 14, 859-869.	1.2	48
133	Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice. Science Translational Medicine, 2012, 4, 141ra91.	12.4	147
134	Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. British Journal of Cancer, 2012, 107, 1409-1417.	6.4	24
135	Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia, 2012, 26, 2039-2051.	7.2	171
136	Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers. Genome Biology, 2012, 13, R95.	9.6	64
137	Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nature Cell Biology, 2012, 14, 958-965.	10.3	79
138	Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC Cancer, 2012, 12, 285.	2.6	25
139	Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. British Journal of Cancer, 2012, 107, 1418-1422.	6.4	151
140	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature Genetics, 2012, 44, 1199-1206.	21.4	336
141	N-Cadherin in Neuroblastoma Disease: Expression and Clinical Significance. PLoS ONE, 2012, 7, e31206.	2.5	39
142	Dickkopf3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. International Journal of Cancer, 2012, 130, 2591-2598.	5.1	43
143	Identification of a novel recurrent 1q42.2-qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. International Journal of Cancer, 2012, 130, 2599-2606.	5.1	37
144	PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. British Journal of Haematology, 2012, 156, 76-88.	2.5	48

#	ARTICLE	IF	CITATIONS
145	High-risk clonal evolution in chronic <scp>B</scp>-cell lymphocytic leukemia: single-center interphase fluorescence <i>in situ</i> hybridization study and review of the literature. European Journal of Haematology, 2012, 89, 72-80.	2.2	20
146	Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of <i>E2F</i> target genes and a poor prognosis. Genes Chromosomes and Cancer, 2012, 51, 10-19.	2.8	57
147	Isolation of disseminated neuroblastoma cells from bone marrow aspirates for pretreatment risk assessment by array comparative genomic hybridization. International Journal of Cancer, 2012, 130, 1098-1108.	5.1	7
148	Cancer Gene Prioritization for Targeted Resequencing Using FitSNP Scores. PLoS ONE, 2012, 7, e31333.	2.5	2
149	Measurable impact of RNA quality on gene expression results from quantitative PCR. Nucleic Acids Research, 2011, 39, e63-e63.	14.5	146
150	A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nature Genetics, 2011, 43, 673-678.	21.4	244
151	Soft tissue tumors: Clear cell sarcoma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
152	ATBF1 (AT-binding transcription factor 1). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
153	EV1-mediated down regulation of <i>MIR449A</i> is essential for the survival of EV1 positive leukaemic cells. British Journal of Haematology, 2011, 154, 337-348.	2.5	20
154	Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene, 2011, 30, 2173-2180.	5.9	87
155	PHF6 mutations in adult acute myeloid leukemia. Leukemia, 2011, 25, 130-134.	7.2	142
156	MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death and Differentiation, 2011, 18, 974-984.	11.2	133
157	Neuroblastoma genetics and phenotype: A tale of heterogeneity. Seminars in Cancer Biology, 2011, 21, 238-244.	9.6	25
158	Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3. Molecular Cancer Therapeutics, 2011, 10, 983-993.	4.1	61
159	miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples. Clinical Cancer Research, 2011, 17, 7684-7692.	7.0	92
160	High <i>ALK</i> Receptor Tyrosine Kinase Expression Supersedes <i>ALK</i> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma. Clinical Cancer Research, 2011, 17, 5082-5092.	7.0	95
161	A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research, 2011, 17, 792-804.	7.0	39
162	Neuroblastoma epigenetics: From candidate gene approaches to genome-wide screenings. Epigenetics, 2011, 6, 962-970.	2.7	50

#	ARTICLE	IF	CITATIONS
163	The microRNA body map: dissecting microRNA function through integrative genomics. Nucleic Acids Research, 2011, 39, e136-e136.	14.5	72
164	Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies. PLoS ONE, 2011, 6, e26311.	2.5	17
165	<i>PRDM16</i> (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.. Journal of Clinical Oncology, 2011, 29, 6531-6531.	1.6	1
166	In Childhood B-Lineage Acute Lymphoblastic Leukemia (B-ALL) with Hyperdiploidy >50 Chromosomes, Patients with 58 to 66 Chromosomes Have 99% EFS At 6-Year Follow-up: Results of the EORTC CLG 58951 Trial. Blood, 2011, 118, 565-565.	1.4	1
167	Regulatory Networks Governed by MicroRNAs in T-ALL Oncogenesis and Normal T-Cell Development. Blood, 2011, 118, 1366-1366.	1.4	0
168	Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma. BMC Genomics, 2010, 11, 298.	2.8	29
169	Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer, 2010, 116, 3233-3243.	4.1	39
170	Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. International Journal of Cancer, 2010, 127, 2374-2385.	5.1	88
171	Giant axonal neuropathy caused by compound heterozygosity for a maternally inherited microdeletion and a paternal mutation within the <i>GAN</i> gene. American Journal of Medical Genetics, Part A, 2010, 152A, 2802-2804.	1.2	19
172	MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene, 2010, 29, 1394-1404.	5.9	112
173	An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene, 2010, 29, 3583-3592.	5.9	141
174	miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nature Cell Biology, 2010, 12, 247-256.	10.3	1,216
175	PHF6 mutations in T-cell acute lymphoblastic leukemia. Nature Genetics, 2010, 42, 338-342.	21.4	282
176	The TLX1 oncogene drives aneuploidy in T cell transformation. Nature Medicine, 2010, 16, 1321-1327.	30.7	139
177	Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11qâ~ Neuroblastoma. Clinical Cancer Research, 2010, 16, 2971-2978.	7.0	70
178	The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors. Molecular Cancer Therapeutics, 2010, 9, 3145-3157.	4.1	14
179	Prognostic Impact of Gene Expressionâ€Based Classification for Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3506-3515.	1.6	129
180	NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia, 2010, 24, 2023-2031.	7.2	125

#	ARTICLE	IF	CITATIONS
181	methGraph: A genome visualization tool for PCR-based methylation assays. <i>Epigenetics</i> , 2010, 5, 159-163.	2.7	3
182	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF- β Pathway in Neuroblastoma. <i>Molecular Cell</i> , 2010, 40, 762-773.	9.7	279
183	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. <i>Clinical Cancer Research</i> , 2010, 16, 1532-1541.	7.0	86
184	Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification. <i>Clinical Cancer Research</i> , 2010, 16, 4353-4362.	7.0	243
185	Identification of Two Critically Deleted Regions within Chromosome Segment 7q35-q36 in EVI1 Deregulated Myeloid Leukemia Cell Lines. <i>PLoS ONE</i> , 2010, 5, e8676.	2.5	19
186	Abstract 1949: Positive feedback regulation between EWS-FLI1 and miR-145 in Ewing's sarcoma. , 2010, , .		0
187	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 471-471.	1.4	0
188	Predicting outcomes for children with neuroblastoma. <i>Discovery Medicine</i> , 2010, 10, 29-36.	0.5	15
189	Widespread Dysregulation of MiRNAs by MYCN Amplification and Chromosomal Imbalances in Neuroblastoma: Association of miRNA Expression with Survival. <i>PLoS ONE</i> , 2009, 4, e7850.	2.5	112
190	Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds. <i>Clinical Cancer Research</i> , 2009, 15, 3690-3696.	7.0	41
191	Disease-Causing 7.4 kb Cis-Regulatory Deletion Disrupting Conserved Non-Coding Sequences and Their Interaction with the FOXL2 Promotor: Implications for Mutation Screening. <i>PLoS Genetics</i> , 2009, 5, e1000522.	3.5	83
192	Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1562-1574.	6.3	105
193	RTPrimerDB: the portal for real-time PCR primers and probes. <i>Nucleic Acids Research</i> , 2009, 37, D942-D945.	14.5	132
194	External oligonucleotide standards enable cross laboratory comparison and exchange of real-time quantitative PCR data. <i>Nucleic Acids Research</i> , 2009, 37, e138-e138.	14.5	25
195	Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1026-1033.	1.6	288
196	RNA pre-amplification enables large-scale RT-qPCR gene-expression studies on limiting sample amounts. <i>BMC Research Notes</i> , 2009, 2, 235.	1.4	38
197	Adenovirus-mediated <i>hPNPase</i> gene transfer as a therapeutic strategy for neuroblastoma. <i>Journal of Cellular Physiology</i> , 2009, 219, 707-715.	4.1	13
198	Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: A Belgian multicentric study. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 843-853.	2.8	54

#	ARTICLE	IF	CITATIONS
199	Array comparative genomic hybridization and flow cytometry analysis of spontaneous abortions and mors in utero samples. BMC Medical Genetics, 2009, 10, 89.	2.1	64
200	Comparison of miRNA profiles of microdissected Hodgkin/Reedâ€ Sternberg cells and Hodgkin cell lines <i>versus</i> CD77⁺ Bâ€ cells reveals a distinct subset of differentially expressed miRNAs. British Journal of Haematology, 2009, 147, 686-690.	2.5	55
201	Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia, 2009, 23, 85-94.	7.2	49
202	Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis. Cell Death and Differentiation, 2009, 16, 1563-1572.	11.2	54
203	International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British Journal of Cancer, 2009, 100, 1471-1482.	6.4	330
204	Unusual 8p inverted duplication deletion with telomere capture from 8q. European Journal of Medical Genetics, 2009, 52, 31-36.	1.3	26
205	The 12q14 microdeletion syndrome: Additional patients and further evidence that HMGA2 is an important genetic determinant for human height. European Journal of Medical Genetics, 2009, 52, 101-107.	1.3	46
206	Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Letters, 2009, 273, 336-346.	7.2	54
207	Challenges for CNV interpretation in clinical molecular karyotyping: Lessons learned from a 1001 sample experience. European Journal of Medical Genetics, 2009, 52, 398-403.	1.3	90
208	Chromosome 3p Microsatellite Allelotyping in Neuroblastoma: A Report on the Technical Hurdles. Cancer Investigation, 2009, 27, 857-868.	1.3	0
209	A novel and universal method for microRNA RT-qPCR data normalization. Genome Biology, 2009, 10, R64.	9.6	849
210	The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Medicine, 2009, 1, 74.	8.2	34
211	Smoothing waves in array CGH tumor profiles. Bioinformatics, 2009, 25, 1099-1104.	4.1	76
212	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology, The, 2009, 10, 663-671.	10.7	176
213	59-gene prognostic signature sub-stratifies high-risk neuroblastoma patients. Lancet Oncology, The, 2009, 10, 1030.	10.7	11
214	Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome. Journal of Medical Genetics, 2009, 46, 511-523.	3.2	250
215	Prognostic Significance of NOTCH1 and FBXW7 Mutations in Childhood T-Cell Acute Lymphoblastic Leukemia (T-ALL): Results From the EORTC Children Leukemia Group.. Blood, 2009, 114, 909-909.	1.4	1
216	Downregulation of MiR-449a Is Essential for the Survival of EVI1 Positive Leukemic Cells through Modulation of NOTCH1 and BCL2.. Blood, 2009, 114, 361-361.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. <i>International Journal of Cancer</i> , 2008, 122, 1177-1182.	5.1	22
218	Aberrant splicing of the <i>PTPRD</i> gene mimics microdeletions identified at this locus in neuroblastomas. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 197-202.	2.8	22
219	Delineation of a critical region on chromosome 18 for the del(18)(q12.2q21.1) syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2008, 146A, 1330-1334.	1.2	28
220	Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hémato-matologique. <i>Leukemia</i> , 2008, 22, 1567-1575.	7.2	64
221	Identification of ALK as a major familial neuroblastoma predisposition gene. <i>Nature</i> , 2008, 455, 930-935.	27.8	1,207
222	Hyperdiploid karyotypes in acute myeloid leukemia define a novel entity: a study of 38 patients from the Groupe Francophone de Cytogénétique Hématologique (GFCH). <i>Leukemia</i> , 2008, 22, 132-137.	7.2	24
223	CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. <i>BMC Cancer</i> , 2008, 8, 173.	2.6	34
224	EV1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22). <i>BMC Cancer</i> , 2008, 8, 193.	2.6	8
225	Copy number alterations and copy number variation in cancer: close encounters of the bad kind. <i>Cytogenetic and Genome Research</i> , 2008, 123, 176-182.	1.1	34
226	A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the the human NBPF1 and ACCN1 genes. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 14.	2.2	0
227	Recurrent Rearrangements of Chromosome 1q21.1 and Variable Pediatric Phenotypes. <i>New England Journal of Medicine</i> , 2008, 359, 1685-1699.	27.0	663
228	Low-cost dedicated mini-arrays for high-throughput analysis of DNA copy-number alterations in neuroblastoma. <i>Cancer Letters</i> , 2008, 269, 111-116.	7.2	2
229	High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. <i>Nucleic Acids Research</i> , 2008, 36, e143-e143.	14.5	261
230	Mapping of 5q35 chromosomal rearrangements within a genomically unstable region. <i>Journal of Medical Genetics</i> , 2008, 45, 672-678.	3.2	7
231	Positional gene enrichment analysis of gene sets for high-resolution identification of overrepresented chromosomal regions. <i>Nucleic Acids Research</i> , 2008, 36, e43-e43.	14.5	56
232	EV1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EV1 to the MSI2 locus at 17q22. <i>Haematologica</i> , 2008, 93, 1903-1907.	3.5	29
233	Use of a genome-wide linkage screen to identify a hereditary neuroblastoma predisposition locus at chromosome 2p24-q23. <i>Journal of Clinical Oncology</i> , 2008, 26, 10010-10010.	1.6	1
234	EGFR and K-RAS gene status evaluation in anal canal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 15569-15569.	1.6	7

#	ARTICLE	IF	CITATIONS
235	A Constitutional Translocation t(1;17)(p36.2;q11.2) in a Neuroblastoma Patient Disrupts the Human NBPF1 and ACCN1 Genes. PLoS ONE, 2008, 3, e2207.	2.5	49
236	MicroRNA Profiling of EVI1 Deregulated Myeloid Leukemia. Blood, 2008, 112, 5322-5322.	1.4	0
237	MicroRNA signatures in Genetic Subtypes of T-Cell Acute Lymphoblastic Leukemia.. Blood, 2008, 112, 3360-3360.	1.4	1
238	Comparison of miRNA Profiles of Microdissected Hodgkin/Reed-Sternberg Cells and Hodgkin Cell Lines Versus CD77+ B-Cells Reveals a Distinct Subset of Differentially Expressed miRNAs. Blood, 2008, 112, 4488-4488.	1.4	0
239	Improved Detection of Chromosomal Abnormalities in CLL by Conventional Cytogenetics Using CpG Oligonucleotide and Interleukin-2 Stimulation. A Belgian Multicentric Study. Blood, 2008, 112, 3118-3118.	1.4	0
240	Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome. Clinical Cancer Research, 2007, 13, 1459-1465.	7.0	28
241	Detection of DNA copy number alterations in cancer by array comparative genomic hybridization. Genetics in Medicine, 2007, 9, 574-584.	2.4	36
242	Real-Time Quantitative PCR as an Alternative to Southern Blot or Fluorescence <i>In Situ</i> Hybridization for Detection of Gene Copy Number Changes. , 2007, 353, 205-226.		64
243	Osteopoikilosis, short stature and mental retardation as key features of a new microdeletion syndrome on 12q14. Journal of Medical Genetics, 2007, 44, 264-268.	3.2	58
244	Mapping biomedical concepts onto the human genome by mining literature on chromosomal aberrations. Nucleic Acids Research, 2007, 35, 2533-2543.	14.5	27
245	Report of a female patient with mental retardation and tall stature due to a chromosomal rearrangement disrupting the OPHN1 gene on Xq12. European Journal of Medical Genetics, 2007, 50, 446-454.	1.3	16
246	Molecular Dissection of Isolated Disease Features in Mosaic Neurofibromatosis Type 1. American Journal of Human Genetics, 2007, 81, 243-251.	6.2	157
247	qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biology, 2007, 8, R19.	9.6	3,580
248	A detailed inventory of DNA copy number alterations in four commonly used Hodgkin's lymphoma cell lines. Haematologica, 2007, 92, 913-920.	3.5	33
249	Subtelomeric imbalances in phenotypically normal individuals. Human Mutation, 2007, 28, 958-967.	2.5	72
250	High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors. International Journal of Cancer, 2007, 120, 533-538.	5.1	20
251	ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes and Cancer, 2007, 46, 1098-1108.	2.8	67
252	Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nature Genetics, 2007, 39, 593-595.	21.4	252

#	ARTICLE	IF	CITATIONS
253	Guidelines for molecular karyotyping in constitutional genetic diagnosis. <i>European Journal of Human Genetics</i> , 2007, 15, 1105-1114.	2.8	144
254	Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCR β -HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique. <i>Leukemia</i> , 2007, 21, 121-128.	7.2	43
255	MicroRNA Profiling of EVI1 Deregulated Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 4146-4146.	1.4	0
256	Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. <i>Genome Biology</i> , 2006, 7, R84.	9.6	134
257	Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements. <i>Leukemia</i> , 2006, 20, 319-321.	7.2	30
258	HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocation. <i>Leukemia</i> , 2006, 20, 1184-1187.	7.2	31
259	Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence of TCR β locus rearrangements and putative new T-cell oncogenes. <i>Leukemia</i> , 2006, 20, 1238-1244.	7.2	72
260	Real-time quantitative allele discrimination assay using 3' locked nucleic acid primers for detection of low-percentage mosaic mutations. <i>Analytical Biochemistry</i> , 2006, 359, 144-146.	2.4	14
261	Culturing in vitro produced blastocysts in sequential media promotes ES cell derivation. <i>Molecular Reproduction and Development</i> , 2006, 73, 1017-1021.	2.0	7
262	Screening for EVI1: ectopic expression absent in T-cell acute lymphoblastic leukemia patients and cell lines. <i>Cancer Genetics and Cytogenetics</i> , 2006, 171, 79-80.	1.0	8
263	Expression profiling suggests underexpression of the GABAA receptor subunit γ in the fragile X knockout mouse model. <i>Neurobiology of Disease</i> , 2006, 21, 346-357.	4.4	151
264	methBLAST and methPrimerDB: web-tools for PCR based methylation analysis. <i>BMC Bioinformatics</i> , 2006, 7, 496.	2.6	35
265	Translocation "excision" deletion "amplification" mechanism leading to nonsyntenic coamplification of <i>MYC</i> and <i>ATBF1</i> . <i>Genes Chromosomes and Cancer</i> , 2006, 45, 107-117.	2.8	47
266	EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 349-356.	2.8	51
267	GAB2 is a novel target of 11q amplification in AML/MDS. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 798-807.	2.8	50
268	Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 893-904.	2.8	56
269	Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. <i>Human Mutation</i> , 2006, 27, 1030-1040.	2.5	105
270	The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma. <i>International Journal of Cancer</i> , 2006, 119, 624-629.	5.1	14

#	ARTICLE	IF	CITATIONS
271	RTPrimerDB: the real-time PCR primer and probe database, major update 2006. <i>Nucleic Acids Research</i> , 2006, 34, D684-D688.	14.5	107
272	Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma. <i>Cancer Research</i> , 2006, 66, 9646-9655.	0.9	132
273	Genome wide measurement of DNA copy number changes in neuroblastoma: dissecting amplicons and mapping losses, gains and breakpoints. <i>Cytogenetic and Genome Research</i> , 2006, 115, 273-282.	1.1	16
274	Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports. <i>Journal of Medical Genetics</i> , 2006, 43, 625-633.	3.2	342
275	Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. <i>Human Molecular Genetics</i> , 2006, 15, 1015-1023.	2.9	195
276	Familial pericentric inversion of chromosome 18: behavioral abnormalities in patients heterozygous for either the dup(18p)/del(18q) or dup(18q)/del(18p) recombinant chromosome. <i>European Journal of Human Genetics</i> , 2005, 13, 52-58.	2.8	18
277	A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. <i>Leukemia</i> , 2005, 19, 358-366.	7.2	106
278	Rapid detection of VHL exon deletions using real-time quantitative PCR. <i>Laboratory Investigation</i> , 2005, 85, 24-33.	3.7	102
279	HOXA gene cluster rearrangement in a t(7;9)(p15;q34) in a child with MDS. <i>Cancer Genetics and Cytogenetics</i> , 2005, 162, 82-84.	1.0	2
280	arrayCGHbase: an analysis platform for comparative genomic hybridization microarrays. <i>BMC Bioinformatics</i> , 2005, 6, 124.	2.6	79
281	Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11. <i>BMC Genomics</i> , 2005, 6, 97.	2.8	19
282	PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 218-223.	2.8	72
283	An interstitial deletion of chromosome 7 at band q21: A case report and review. , 2005, 134A, 12-23.		23
284	Impact of RNA quality on reference gene expression stability. <i>BioTechniques</i> , 2005, 39, 52-56.	1.8	92
285	A Novel Gene Family NBPF: Intricate Structure Generated by Gene Duplications During Primate Evolution. <i>Molecular Biology and Evolution</i> , 2005, 22, 2265-2274.	8.9	128
286	Molecular Karyotyping: Array CGH Quality Criteria for Constitutional Genetic Diagnosis. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 413-422.	2.5	141
287	Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 2280-2299.	1.6	160
288	No Evidence for Correlation of DDX1 Gene Amplification With Improved Survival Probability in Patients With MYCN-Amplified Neuroblastomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 3167-3168.	1.6	24

#	ARTICLE	IF	CITATIONS
289	Identification of an unbalanced X-autosome translocation by array CGH in a boy with a syndromic form of chondrodysplasia punctata brachytelephalangi type. <i>European Journal of Medical Genetics</i> , 2005, 48, 301-309.	1.3	18
290	Novel cryptic chromosomal rearrangements in childhood acute lymphoblastic leukemia detected by multiple color fluorescent in situ hybridization. <i>Haematologica</i> , 2005, 90, 1179-85.	3.5	12
291	Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. <i>Nature Genetics</i> , 2004, 36, 1213-1218.	21.4	410
292	Claes Lundsteen "in Memoriam. <i>European Journal of Human Genetics</i> , 2004, 12, 603-603.	2.8	0
293	Translocation t(2;3)(p15;q26) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. <i>Leukemia</i> , 2004, 18, 1108-1114.	7.2	33
294	Gene-expression profiling reveals distinct expression patterns for Classic versus Variant Merkel cell phenotypes and new classifier genes to distinguish Merkel cell from small-cell lung carcinoma. <i>Oncogene</i> , 2004, 23, 2732-2742.	5.9	63
295	Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation. <i>Laboratory Investigation</i> , 2004, 84, 406-417.	3.7	49
296	Combined subtractive cDNA cloning and array CGH: an efficient approach for identification of overexpressed genes in DNA amplicons. <i>BMC Genomics</i> , 2004, 5, 11.	2.8	22
297	No evidence for involvement of SDHD in neuroblastoma pathogenesis. <i>BMC Cancer</i> , 2004, 4, 55.	2.6	17
298	Molecular cytogenetic analysis of complex chromosomal rearrangements in patients with mental retardation and congenital malformations: Delineation of 7q21.11 breakpoints. <i>American Journal of Medical Genetics Part A</i> , 2004, 124A, 10-18.	2.4	19
299	Molecular analysis of the putative tumour-suppressor gene EXTL1 in neuroblastoma patients and cell lines. <i>European Journal of Cancer</i> , 2004, 40, 1255-1261.	2.8	10
300	Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. <i>Blood</i> , 2004, 103, 442-450.	1.4	141
301	Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. <i>Blood</i> , 2004, 103, 229-235.	1.4	117
302	Evidence for involvement of a tumor suppressor gene on 1p in malignant peripheral nerve sheath tumors. <i>Cancer Genetics and Cytogenetics</i> , 2003, 143, 120-124.	1.0	7
303	Quantitative real time polymerase chain reaction for measurement of human interleukin-5 receptor alpha spliced isoforms mRNA. <i>BMC Biotechnology</i> , 2003, 3, 17.	3.3	18
304	t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Français de Cytogénétique Hématologique (GFCH). <i>Leukemia</i> , 2003, 17, 1851-1857.	7.2	79
305	ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. <i>Oncogene</i> , 2003, 22, 456-460.	5.9	38
306	Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. <i>Nature Genetics</i> , 2003, 33, 463-465.	21.4	764

#	ARTICLE	IF	CITATIONS
307	Gene Expression Profiling Reveals Two Distinct Subtypes of Merkel Cell Carcinoma. , 2003, , 195-202.		1
308	Expression of Developmentally Regulated Transcription Factors in Merkel Cell Carcinoma. , 2003, , 203-218.		0
309	Application of laser capture microdissection in genetic analysis of neuroblastoma and neuroblastoma precursor cells. Cancer Letters, 2003, 197, 53-61.	7.2	28
310	RTPrimerDB: the Real-Time PCR primer and probe database. Nucleic Acids Research, 2003, 31, 122-123.	14.5	240
311	Quality Assessment of Genetic Markers Used for Therapy Stratification. Journal of Clinical Oncology, 2003, 21, 2077-2084.	1.6	113
312	ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood, 2003, 102, 2638-2641.	1.4	174
313	Regulation of Peroxisomal Genes by DHEA and Vitamin D. Advances in Experimental Medicine and Biology, 2003, 544, 237-242.	1.6	2
314	Modulation of the peroxisomal gene expression pattern by dehydroepiandrosterone and vitamin D: therapeutic implications. Journal of Endocrinology, 2002, 175, 779-792.	2.6	35
315	Molecular cytogenetic analysis of 10;11 rearrangements in acute myeloid leukemia. Leukemia, 2002, 16, 344-351.	7.2	50
316	Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology, 2002, 3, RESEARCH0034.	9.6	16,304
317	Quantification of MYCN, DDX1, and NAG Gene Copy Number in Neuroblastoma Using a Real-Time Quantitative PCR Assay. Modern Pathology, 2002, 15, 159-166.	5.5	167
318	A brief commentary on "Chromosomal aberrations in neuroblastoma cell lines identified by cross species color banding and chromosome painting". Cancer Genetics and Cytogenetics, 2002, 135, 196.	1.0	2
319	Kallmann syndrome in a patient with congenital spherocytosis and an interstitial 8p11.2 deletion. American Journal of Medical Genetics Part A, 2002, 108, 315-318.	2.4	37
320	Elimination of Primer-Dimer Artifacts and Genomic Coamplification Using a Two-Step SYBR Green I Real-Time RT-PCR. Analytical Biochemistry, 2002, 303, 95-98.	2.4	201
321	Proneural and proneuroendocrine transcription factor expression in cutaneous mechanoreceptor (Merkel) cells and Merkel cell carcinoma. International Journal of Cancer, 2002, 101, 103-110.	5.1	68
322	Combined karyotyping, CGH and FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in Merkel cell carcinoma. International Journal of Cancer, 2002, 101, 137-145.	5.1	80
323	Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between the ACCN1 and TLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients. Genes Chromosomes and Cancer, 2002, 35, 113-120.	2.8	21
324	Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using FISH. Genes Chromosomes and Cancer, 2002, 33, 60-72.	2.8	98

#	ARTICLE	IF	CITATIONS
325	Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. International Journal of Cancer, 2001, 91, 680-686.	5.1	112
326	Detailed characterization of 12 supernumerary ring chromosomes using micro-FISH and search for uniparental disomy. American Journal of Medical Genetics Part A, 2001, 99, 223-233.	2.4	68
327	Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 20-23.	1.0	13
328	Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there?. Medical and Pediatric Oncology, 2001, 36, 5-10.	1.0	82
329	Frequent allelic loss at 10q23 but low incidence of PTEN mutations in merkel cell carcinoma. International Journal of Cancer, 2001, 92, 409-413.	5.1	63
330	Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines. Genes Chromosomes and Cancer, 2001, 32, 126-135.	2.8	46
331	Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes and Cancer, 2001, 30, 274-282.	2.8	103
332	Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genetics and Cytogenetics, 2001, 128, 39-42.	1.0	56
333	Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes and Development, 2001, 15, 2250-2262.	5.9	181
334	Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes and Cancer, 2001, 30, 274-282.	2.8	3
335	Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes and Cancer, 2001, 30, 274-82.	2.8	23
336	An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis. Genes Chromosomes and Cancer, 2000, 27, 143-152.	2.8	21
337	Subtelomeric familial translocation t(2;7)(q37;q35) leading to partial trisomy 7q35?pter: Molecular cytogenetic analysis and clinical phenotype in two generations. American Journal of Medical Genetics Part A, 2000, 93, 349-354.	2.4	24
338	Chromosome 2 short arm translocations revealed by M-FISH analysis of neuroblastoma cell lines. Medical and Pediatric Oncology, 2000, 35, 538-540.	1.0	17
339	Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Human Mutation, 2000, 15, 541-555.	2.5	477
340	Structure and mutation analysis of the gene encoding DNA fragmentation factor 40 (caspase-activated) Tj ETQq0 Q.0 rgBT /Overlock 10	3.8	28
341	Mutation analysis of P73 and TP53 in Merkel cell carcinoma. British Journal of Cancer, 2000, 82, 823-826.	6.4	94
342	Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. , 2000, 15, 541.		4

#	ARTICLE	IF	CITATIONS
343	Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Human Mutation, 2000, 15, 541.	2.5	6
344	Subtelomeric familial translocation t(2;7)(q37;q35) leading to partial trisomy 7q35→qter: molecular cytogenetic analysis and clinical phenotype in two generations. American Journal of Medical Genetics Part A, 2000, 93, 349-54.	2.4	1
345	Refined physical mapping and genomic structure of the EXTL1 gene. Cytogenetic and Genome Research, 1999, 86, 267-270.	1.1	11
346	The β -catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells. Oncogene, 1999, 18, 905-915.	5.9	73
347	Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 396-403.	6.4	19
348	Delineation of two distinct 6p deletion syndromes. Human Genetics, 1999, 104, 64-72.	3.8	108
349	Gain of Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma. New England Journal of Medicine, 1999, 340, 1954-1961.	27.0	456
350	Closing in on the BPES Gene on 3q23: Mapping of a de Novo Reciprocal Translocation t(3;4)(q23;p15.2) Breakpoint within a 45-kb Cosmid and Mapping of Three Candidate Genes, RBP1, RBP2, and β -COP, Distal to the Breakpoint. Genomics, 1999, 57, 70-78.	2.9	32
351	Mapping of novel regions of DNA gain and loss by comparative genomic hybridization in esophageal carcinoma in the Black and Colored populations of South Africa. Cancer Research, 1999, 59, 1877-83.	0.9	51
352	Did the Four Human Cancer Cell Lines DLD-1, HCT-15, HCT-8, and HRT-18 Originate from One and the Same Patient?. Cancer Genetics and Cytogenetics, 1998, 107, 76-79.	1.0	42
353	Cytogenetic and molecular analysis of cellular atypical mesoblastic nephroma. , 1998, 21, 265-269.		16
354	FISH identifies inv(16)(p13q22) masked by translocations in three cases of acute myeloid leukemia. , 1998, 22, 87-94.		23
355	Molecular analysis of 1p36 breakpoints in two Merkel cell carcinomas. , 1998, 23, 67-71.		30
356	Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines. , 1998, 23, 116-122.		36
357	Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes and Cancer, 1998, 23, 141-152.	2.8	121
358	Noonan-like phenotype in monozygotic twins with a duplication-deficiency of the long arm of chromosome 18 resulting from a maternal paracentric inversion. Human Genetics, 1998, 103, 497-505.	3.8	23
359	Ossified retroperitoneal malignant Schwannoma with spinal leptomeningeal metastases. Neuroradiology, 1998, 40, 48-50.	2.2	10
360	Identification of a Third EXT-like Gene (EXTL3) Belonging to the EXT Gene Family. Genomics, 1998, 47, 230-237.	2.9	124

#	ARTICLE	IF	CITATIONS
361	Assignment<footref rid="foot01">¹</footref> of the cellular retinol-binding protein 1 gene (RBP1) and of the coatomer beta' subunit gene (COPB2) to human chromosome band 3q23 by in situ hybridization. Cytogenetic and Genome Research, 1998, 82, 226-227.	1.1	13
362	Assignment<footref rid="foot01">¹</footref> of the cellular retinol-binding protein 2 gene (RBP2) to human chromosome band 3q23 by in situ hybridization. Cytogenetic and Genome Research, 1998, 83, 240-241.	1.1	11
363	Assignment<footref rid="foot01">¹</footref> of SHOX2 (alias OG12X and SHOT) to human chromosome bands 3q25â†'q26.1 by in situ hybridization. Cytogenetic and Genome Research, 1998, 82, 228-229.	1.1	13
364	Characteristic pattern of chromosomal gains and losses in Merkel cell carcinoma detected by comparative genomic hybridization. Cancer Research, 1998, 58, 1503-8.	0.9	58
365	Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis. European Journal of Cancer, 1997, 33, 1979-1982.	2.8	32
366	Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes. European Journal of Cancer, 1997, 33, 1974-1978.	2.8	36
367	Mutation of ?-Catenin Results in Invasiveness of Human HCT-8 Colon Cancer Cells. Annals of the New York Academy of Sciences, 1997, 833, 186-189.	3.8	10
368	Improved protocol for the preparation of chromatin fibres from fixed cells. Technical Tips Online, 1997, 2, 124-125.	0.2	6
369	Comparative genomic hybridization analysis of human neuroblastomas: Detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines. Cancer Genetics and Cytogenetics, 1997, 97, 135-142.	1.0	39
370	Amplification units and translocation at chromosome 17q and c-erb B-2 overexpression in the pathogenesis of breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 430, 365-372.	2.8	40
371	Interstitial telomeric sequences at the junction site of a jumping translocation. Human Genetics, 1997, 99, 735-737.	3.8	57
372	Interstitial deletion 2q33.3-q34 in a boy with a phenotype resembling the Seckel syndrome. American Journal of Medical Genetics Part A, 1997, 71, 479-485.	2.4	23
373	Monosomy 22 in a mixed germ cell-sex cord-stromal tumor of the ovary. Genes Chromosomes and Cancer, 1997, 19, 192-194.	2.8	18
374	Identification and Characterization of a Novel Member of the EXT Gene Family, EXTL2. European Journal of Human Genetics, 1997, 5, 382-389.	2.8	77
375	Malignant melanoma of the soft parts (clear-cell sarcoma): confirmation of EWS and ATF-1 gene fusion caused by a t(12;22) translocation. Modern Pathology, 1997, 10, 496-9.	5.5	38
376	Monosomy 22 in a mixed germ cell-sex cord-stromal tumor of the ovary. Genes Chromosomes and Cancer, 1997, 19, 192-4.	2.8	8
377	Identification and characterization of a novel member of the EXT gene family, EXTL2. European Journal of Human Genetics, 1997, 5, 382-9.	2.8	21
378	Reassignment of MYCL1 to human chromosome 1p34.3 by fluorescence in situ hybridization. Cytogenetic and Genome Research, 1996, 72, 189-190.	1.1	14

#	ARTICLE	IF	CITATIONS
379	Multiple polysomies in nasal polyps in children. <i>Cancer Genetics and Cytogenetics</i> , 1996, 90, 86-87.	1.0	4
380	Mosaic tetrasomy 15q25â†’qter in a newborn infant with multiple anomalies. <i>American Journal of Medical Genetics Part A</i> , 1996, 63, 482-485.	2.4	31
381	A human modifier of methylation for class I HLA genes (MEMO-1) maps to chromosomal bands 1p35-36.1. <i>Human Molecular Genetics</i> , 1996, 5, 309-317.	2.9	21
382	Localization by fluorescence in situ hybridization of the human functional Î²-glucuronidase gene (GUSB) to 7q11.21â†’q11.22 and two pseudogenes to 5p13 and 5q13. <i>Cytogenetic and Genome Research</i> , 1996, 1.1 72, 53-55.		14
383	Refined Genetic and Physical Mapping of BPES Type II. <i>European Journal of Human Genetics</i> , 1996, 4, 34-38.	2.8	20
384	Balanced translocation in a neuroblastoma patient disrupts a cluster of small nuclear RNA UI and tRNA genes in chromosomal band 1p36. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 35-42.	2.8	22
385	Full triploidy in a liveborn preterm infant. <i>European Journal of Pediatrics</i> , 1995, 154, 688-688.	2.7	1
386	Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP. <i>Cancer Genetics and Cytogenetics</i> , 1995, 82, 151-154.	1.0	43
387	Micronucleus Induction in Peripheral Blood Lymphocytes of Patients under Radiotherapy Treatment for Cervical Cancer or Hodgkin's Disease. <i>International Journal of Radiation Biology</i> , 1995, 67, 529-539.	1.8	45
388	Assignment of the human β-catenin gene (CTNNB1) to 3p22→p21.3 by fluorescence in situ hybridization. <i>Cytogenetic and Genome Research</i> , 1995, 70, 68-70.	1.1	23
389	Evidence for two tumour suppressor loci on chromosomal bands 1p35â€³36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. <i>Human Molecular Genetics</i> , 1995, 4, 535-539.	2.9	154
390	Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma. <i>European Journal of Cancer</i> , 1995, 31, 530-535.	2.8	35
391	Characterisation of the chromosome breakpoints in a patient with a constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12) and neuroblastoma. <i>European Journal of Cancer</i> , 1995, 31, 523-526.	2.8	14
392	1p36: Every subband a suppressor?. <i>European Journal of Cancer</i> , 1995, 31, 538-541.	2.8	60
393	Constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12.1) in a neuroblastoma patient. Establishment of somatic cell hybrids and identification of PND/A12M2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers. <i>Oncogene</i> , 1995, 10, 1087-93.	5.9	35
394	Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. <i>Oncogene</i> , 1995, 10, 291-7.	5.9	101
395	The gene for human gap junction protein connexin37 (GJA4) maps to chromosome 1p35.1, in the vicinity of D1S195. <i>Genomics</i> , 1995, 30, 402-3.	2.9	11
396	Localization of the gene (RSN) coding for restin, a marker for Reed-Sternberg cells in Hodgkinâ€™s disease, to human chromosome band 12q24.3 and YAC cloning of the locus. <i>Cytogenetic and Genome Research</i> , 1994, 65, 172-176.	1.1	15

#	ARTICLE	IF	CITATIONS
397	A multimegabase cluster of snRNA and tRNA genes on chromosome 1p36 harbours an adenovirus/SV40 hybrid virus integration site. Human Molecular Genetics, 1994, 3, 2131-2136.	2.9	18
398	1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes and Cancer, 1994, 10, 103-114.	2.8	134
399	Proximal deletion of chromosome 21 confirmed by in situ hybridization and molecular studies. American Journal of Medical Genetics Part A, 1994, 51, 260-265.	2.4	19
400	Six cases of 7p deletion: Clinical, cytogenetic, and molecular studies. American Journal of Medical Genetics Part A, 1994, 51, 270-276.	2.4	57
401	Jumping translocation in a newborn boy with dup (4q) and severe hydrops fetalis. American Journal of Medical Genetics Part A, 1994, 52, 214-217.	2.4	19
402	Chromosome aberrations in fibrous dysplasia. Cancer Genetics and Cytogenetics, 1994, 77, 114-117.	1.0	26
403	The Human MCP-3 Gene (SCYA7): Cloning, Sequence Analysis, and Assignment to the C-C Chemokine Gene Cluster on Chromosome 17q11.2-q12. Genomics, 1994, 21, 403-408.	2.9	37
404	Direct transmission of a tandem duplication in the short arm of chromosome 8. Clinical Genetics, 1994, 45, 36-39.	2.0	14
405	Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. American Journal of Human Genetics, 1994, 55, 341-7.	6.2	58
406	Molecular cytogenetic characterization of marker chromosomes found at prenatal diagnosis. Prenatal Diagnosis, 1993, 13, 385-394.	2.3	16
407	EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nature Genetics, 1993, 4, 341-345.	21.4	483
408	Improved immunocytochemical detection of biotinylated probes with neutralite avidin. Trends in Genetics, 1993, 9, 71-72.	6.7	10
409	High-Resolution Chromosomal Localization of the Human Calcitonin/CGRP/IAPP Gene Family Members. Genomics, 1993, 15, 525-529.	2.9	37
410	High-Resolution Fluorescence Mapping of 46 DNA Markers to the Short Arm of Human Chromosome 1. Genomics, 1993, 18, 71-78.	2.9	64
411	Confirmation of a mosaic dicentric Y chromosome in a female using fluorescence in situ hybridisation. Journal of Obstetrics and Gynaecology, 1993, 13, 266-269.	0.9	0
412	Molecular cytogenetic analysis of a familial pericentric inversion of chromosome 12. Clinical Genetics, 1993, 44, 156-163.	2.0	12
413	Platelet-derived growth factor A chain: Confirmation of localization of PDGFA to chromosome 7p22 and description of an unusual minisatellite. Genomics, 1992, 13, 257-263.	2.9	9
414	Malignant melanoma of soft parts. Cancer Genetics and Cytogenetics, 1992, 60, 176-179.	1.0	31

#	ARTICLE	IF	CITATIONS
415	i(12p) in a near-diploid mature ovarian teratoma. <i>Cancer Genetics and Cytogenetics</i> , 1992, 60, 216-218.	1.0	30
416	Uterine leiomyoma cytogenetics. <i>Cancer Genetics and Cytogenetics</i> , 1992, 62, 40-42.	1.0	19
417	Reciprocal translocation between the proximal regions of the long arms of chromosomes 13 and 15 resulting in unbalanced offspring: characterization by fluorescence in situ hybridization and DNA analysis. <i>Human Genetics</i> , 1992, 89, 407-413.	3.8	5
418	Molecular cytogenetic analysis of XX males using Y-specific DNA sequences, including SRY. <i>Human Genetics</i> , 1992, 89, 23-28.	3.8	27
419	Molecular cytogenetic analysis of a complex t(10;22;11) translocation in ewing's sarcoma. <i>Genes Chromosomes and Cancer</i> , 1992, 4, 188-191.	2.8	17
420	Putative monosomy 21 in two patients: clinical findings and investigation using fluorescence in situ hybridization. <i>Clinical Genetics</i> , 1992, 42, 105-109.	2.0	24
421	Detection of subtle reciprocal translocations by fluorescence in situ hybridization. <i>Clinical Genetics</i> , 1992, 41, 169-174.	2.0	37
422	Familial Turner syndrome. <i>Clinical Genetics</i> , 1992, 41, 218-220.	2.0	16
423	The distal region of 11p13 and associated genetic diseases. <i>Genomics</i> , 1991, 11, 284-293.	2.9	22
424	Analysis of whole-arm translocations in malignant blood cells by nonisotopic in situ hybridization. <i>Cytogenetic and Genome Research</i> , 1991, 56, 14-17.	1.1	19
425	Assignment of the fucosidase pseudogene FUCA1P to chromosome region 2q31â†’q32. <i>Cytogenetic and Genome Research</i> , 1991, 57, 120-122.	1.1	0
426	Is t(6;20)(p21;q13) a characteristic chromosome change in endometrial polyps?. <i>Genes Chromosomes and Cancer</i> , 1991, 3, 318-319.	2.8	20
427	Pallister-killian syndrome: Characterization of the isochromosome 12p by fluorescent In Situ hybridization. <i>American Journal of Medical Genetics Part A</i> , 1991, 41, 381-387.	2.4	65
428	Characterization of a de novo duplication of 11p14→p13, using fluorescent in situ hybridization and Southern hybridization. <i>Cytogenetic and Genome Research</i> , 1991, 56, 129-131.	1.1	11
429	Identification and characterization of normal length nonfluorescent Y chromosomes: cytogenetic analysis, Southern hybridization and non-isotopic in situ hybridization. <i>Human Genetics</i> , 1990, 85, 569-575.	3.8	22
430	Constitutional translocation t(1;17)(p36;q12â€“21) in a patient with neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 1990, 2, 252-254.	2.8	99
431	i(12p) in a malignant ovarian tumor. <i>Cancer Genetics and Cytogenetics</i> , 1990, 45, 49-53.	1.0	65
432	De novo terminal deletion 7p22.1--pter in a child without craniosynostosis.. <i>Journal of Medical Genetics</i> , 1989, 26, 528-532.	3.2	24

#	ARTICLE	IF	CITATIONS
433	Cytogenetic analysis of a mesenchymal hamartoma of the liver. Cancer Genetics and Cytogenetics, 1989, 40, 29-32.	1.0	63
434	Cytogenetic investigation of a case of congenital fibrosarcoma. Cancer Genetics and Cytogenetics, 1989, 39, 21-24.	1.0	43
435	Cytogenetic investigation of pediatric solid tumors with the use of collagenase disaggregation. Cancer Genetics and Cytogenetics, 1989, 38, 165.	1.0	0
436	Translocation 15:19 in a mesenchymal hamartoma. Cancer Genetics and Cytogenetics, 1989, 38, 168.	1.0	0
437	DNA Copy Number Changes and Beyond. Pediatric and Adolescent Medicine, 0, , 10-22.	0.4	0